Compositions and methods for the sustained release of beta-alanine
Methods and compositions are provided for increasing the anaerobic working capacity of muscle and other tissues. Also provided are compositions formulated for the sustained release of free beta-alanine. Also provided is a dietary supplement formulated, for example, as a solid food product, an edible suspension, liquid or semi-liquid as described herein.
1. A human dietary supplement comprising free beta-alanine or a salt of free beta-alanine,
wherein the free beta-alanine or the salt of free beta-alanine is formulated in a matrix for sustained release,
wherein a concentration of beta-alanine in a human's blood does not exceed 200 Σmol/l within 15 minutes after ingestion of the human dietary supplement;
wherein the matrix contains from about 0.1 g to about 10.0 g of the free beta-alanine or the salt of free beta-alanine per serving of the human dietary supplement, and
wherein the human dietary supplement decreases effects of paraesthesia.
2. The human dietary supplement of claim 1 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 1.0 g to about 10 g.
3. The human dietary supplement of claim 1 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 1.0 g to about 9.0 g.
4. The human dietary supplement of claim 1 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 2.0 g to about 8.0 g.
5. The human dietary supplement of claim 1 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 3.0 g to about 7.0 g.
6. The human dietary supplement of claim 1 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 4.0 g to about 6.0 g.
7. The human dietary supplement of claim 1 , wherein the sustained release formulation is in a solid, liquid or semi-liquid.
8. A human dietary supplement comprising free beta-alanine or a salt of free beta-alanine,
wherein the free beta-alanine or the salt of free beta-alanine is formulated in a matrix for sustained release,
wherein a concentration of beta-alanine in a human's blood does not exceed 375 μmol/l within 30 minutes after ingestion of the human dietary supplement;
wherein the matrix contains from about 0.1 g to about 10.0 g of the free beta-alanine or the salt of free beta-alanine per serving of the human dietary supplement, and
wherein the human dietary supplement decreases effects of paraesthesia.
9. The human dietary supplement of claim 8 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 1.0 g to about 10 g.
10. The human dietary supplement of claim 8 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 1.0 g to about 9.0 g.
11. The human dietary supplement of claim 8 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 2.0 g to about 8.0 g.
12. The human dietary supplement of claim 8 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 3.0 g to about 7.0 g.
13. The human dietary supplement of claim 8 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 4.0 g to about 6.0 g.
14. The human dietary supplement of claim 8 , wherein the sustained release formulation is in a solid, liquid or semi-liquid.
15. A human dietary supplement comprising free beta-alanine or a salt of free beta-alanine,
wherein the free beta-alanine or the salt of free beta-alanine is formulated in a matrix for sustained release,
wherein a concentration of beta-alanine in a human's blood does not exceed 300 μmol/l within 45 minutes after ingestion of the human dietary supplement;
wherein the matrix contains from about 0.1 g to about 10.0 g of the free beta-alanine or the salt of free beta-alanine per serving of the human dietary supplement, and
wherein the human dietary supplement decreases effects of paraesthesia.
16. The human dietary supplement of claim 15 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 1.0 g to about 10 g.
17. The human dietary supplement of claim 15 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 1.0 g to about 9.0 g.
18. The human dietary supplement of claim 15 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 2.0 g to about 8.0 g.
19. The human dietary supplement of claim 15 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 3.0 g to about 7.0 g.
20. The human dietary supplement of claim 15 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 4.0 g to about 6.0 g.
21. The human dietary supplement of claim 15 , wherein the sustained release formulation is in a solid, liquid or semi-liquid.
22. A human dietary supplement comprising free beta-alanine or a salt of free beta-alanine,
wherein the free beta-alanine or the salt of free beta-alanine is formulated in a matrix for sustained release,
wherein a concentration of beta-alanine in a human's blood does not exceed 100 μmol/l within 75 minutes after ingestion of the human dietary supplement;
wherein the matrix contains from about 0.1 g to about 10.0 g of the free beta-alanine or the salt of free beta-alanine per serving of the human dietary supplement, and
wherein the human dietary supplement decreases effects of paraesthesia.
23. The human dietary supplement of claim 22 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 1.0 g to about 10 g.
24. The human dietary supplement of claim 22 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 1.0 g to about 9.0 g.
25. The human dietary supplement of claim 22 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 2.0 g to about 8.0 g.
26. The human dietary supplement of claim 22 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 3.0 g to about 7.0 g.
27. The human dietary supplement of claim 22 , wherein the free beta-alanine, or salt thereof, in the sustained release formulation is provided in an amount ranging from about 4.0 g to about 6.0 g.
28. The human dietary supplement of claim 22 , wherein the sustained release formulation is in a solid, liquid or semi-liquid.